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Abstract
Background: In Norway, screening for tuberculosis infection by tuberculin skin test (TST) has been offered for several
decades to all children in 9th grade of school, prior to BCG-vaccination. The incidence of tuberculosis in Norway is low
and infection with M. tuberculosis is considered rare. QuantiFERON®TB Gold (QFT) is a new and specific blood test for
tuberculosis infection. So far, there have been few reports of QFT used in screening of predominantly unexposed,
healthy, TST-positive children, including first and second generation immigrants. In order to evaluate the current TST
screening and BCG-vaccination programme we aimed to (1) measure the prevalence of QFT positivity among TST
positive children identified in the school based screening, and (2) measure the association between demographic and
clinical risk factors for tuberculosis infection and QFT positivity.
Methods: This cross-sectional multi-centre study was conducted during the school year 2005–6 and the TST positive
children were recruited from seven public hospitals covering rural and urban areas in Norway. Participation included a
QFT test and a questionnaire regarding demographic and clinical risk factors for latent infection. All positive QFT results
were confirmed by re-analysis of the same plasma sample. If the confirmatory test was negative the result was reported
as non-conclusive and the participant was offered a new test.
Results: Among 511 TST positive children only 9% (44) had a confirmed positive QFT result. QFT positivity was
associated with larger TST induration, origin outside Western countries and known exposure to tuberculosis. Most
children (79%) had TST reactions in the range of 6–14 mm; 5% of these were QFT positive. Discrepant results between
the tests were common even for TST reactions above 15 mm, as only 22 % had a positive QFT.
Conclusion: The results support the assumption that factors other than tuberculosis infection are widely contributing
to positive TST results in this group and indicate the improved specificity of QFT for latent tuberculosis. Our study
suggests a very low prevalence of latent tuberculosis infection among 9th grade school children in Norway. The result
will inform the discussion in Norway of the usefulness of the current TST screening and BCG-policy.
Published: 17 October 2008
BMC Infectious Diseases 2008, 8:140 doi:10.1186/1471-2334-8-140
Received: 3 March 2008
Accepted: 17 October 2008
This article is available from: http://www.biomedcentral.com/1471-2334/8/140
© 2008 Winje et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases 2008, 8:140 http://www.biomedcentral.com/1471-2334/8/140Background
The incidence of tuberculosis in Norway is generally low
(6.3/100 000 population in 2006), but high among
immigrants from countries where tuberculosis is endemic
[1]. Although the tuberculin skin test (TST) has low specif-
icity, it is still the major tool for detecting tuberculosis
infection. Screening for tuberculosis infection by TST has
in Norway been offered to all children in the 9th grade of
school (age 14–15) for several decades. Historically there
have been three objectives of this screening: (1) to meas-
ure the transmission rate of tuberculosis infection in the
population, (2) to identify cases with latent tuberculosis
infection for preventive treatment, and (3) to ensure that
only tuberculin negative children receive Bacillus Cal-
mette-Guérin (BCG) vaccine, which is offered in the
national vaccination programme to all previously unvac-
cinated, TST negative children at the age of 14 years. Chil-
dren born in Norway of parents from high prevalence
countries and a limited number of other children
assumed to be at risk are offered BCG-vaccination at birth
or on other occasions [2].
Each year, this screening results in several hundred chil-
dren with a positive TST (defined as => 6 mm) being
referred to hospitals for medical evaluation, chest X-ray
and a three year follow up procedure. This requires large
resources and causes concern among the affected families.
No case of tuberculosis disease has been identified
through this screening for many years. We suspect that
previous BCG-vaccination or infection with non-tubercu-
losis mycobacteria (NTM) are the causes of most TST reac-
tions as few of the children have any known exposure to
tuberculosis and the transmission rate in Norway, based
on molecular epidemiology, is known to be very low
[3,4].
New in vitro assays based on cellular production of inter-
feron-gamma (IFN-γ) in response to the M. tuberculosis
specific antigens ESAT-6, CFP10, and TB7.7 have been
developed. These protein antigens are absent in all vaccine
strains of M. bovis-BCG and most NTM, except M. mari-
num, M. szulgai, and M. kansasii [5,6]. In contrast to TST,
these tests can therefore distinguish M. tuberculosis infec-
tion from infections with NTM or previous BCG-vaccina-
tion. The assays seem to be accurate and valid diagnostic
tools for both active and latent tuberculosis infection with
high specificity [6-10]. Among the commercially available
and regulatory approved IFN-γ release assays, the Quan-
tiFERON®TB Gold (QFT) test offers both logistic and eco-
nomical advantages which make it suitable for mass
screening. QFT has now been evaluated and used in differ-
ent contexts. So far, there have been few reports of QFT
used in screening of predominantly unexposed and
healthy TST positive children, including first and second
generation immigrants [6,8,11,12].
The policy of universal TST screening and BCG-vaccina-
tion of school children in Norway is currently under dis-
cussion. In order to evaluate the current TST screening and
BCG-vaccination programme and inform the discussion
on any future targeted screening approach, we aimed to
(1) measure the prevalence of QFT positivity among TST
positive children identified in the school based screening
and (2) measure the association between demographic
and clinical risk factors for tuberculosis infection and QFT
positivity.
Methods
In Norway, all children in the 9th grade of school (age 14–
15) are offered TST screening. TST with purified protein
derivative (PPD) RT 23 (2 TU) from Statens Serum Insti-
tute, Denmark, is applied according to the Mantoux
method and read by public health nurses in the schools.
This antigen is comparable with 5 TU of PPD in the
United States and Canada [13]. A test is considered posi-
tive if the induration is => 6 mm after 72 hours. Children
with a positive TST are referred to the public hospital serv-
ing the area. In this cross-sectional study in the school year
2005–6, we aimed to include all 9th grade children
referred to seven hospitals serving both rural and urban
areas in Norway. After the parents or guardians had given
written informed consent, a QFT test was obtained and a
questionnaire regarding demographic and clinical risk
factors for latent infection, including data on exposure,
was completed. Regardless of participation in the study,
the nationally recommended follow up procedures were
followed.
Statistics Norway provided the number and demographic
characteristics of all children born in 1991 (proxy for 9th
graders) living in the geographical regions covered by the
seven hospitals. The Regional Ethics Committee for Med-
ical Research recommended the study (S-05160) and per-
mission was given from the Norwegian Data Inspectorate
(23147).
The QuantiFERON®TB Gold in-tube-test (Cellestis Ltd,
Victoria, Australia) was used. One ml of venous blood was
drawn into each of two pre-coated tubes with and without
synthetic peptide antigens respectively. A mitogen posi-
tive control was not included since this was not available
in this first version of the test. The samples were processed
and stored in accordance with the manufacturer's instruc-
tions at the local hospital before they were transported to
the Norwegian Institute of Public Health, where harvested
plasma was subjected to Enzyme-Linked Immunosorbent
Assay (ELISA) analysis, including IFN-γ standard for quan-
tification. The quality of all laboratory analysis and calcu-
lation of the results was controlled by the accompanying
QFT analysis software. A sample was considered positive
if exceeding the standard cut-off value at 0.35 IU IFN-γ/Page 2 of 9
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the same plasma sample before they were reported as pos-
itive. If the confirmatory test was negative, the QFT result
was reported as non-conclusive and the participant was
offered a new test.
Participating hospitals entered data into Excel 2003 in a
standardized format and the data were later validated and
merged at the Norwegian Institute of Public Health. Exact
confidence intervals were calculated for proportions of
single samples. Statistical analyses were performed in
STATA 9.2 (Statacorp, Texas, 77845, USA).
For analysis the origin of children was grouped in three:
(1) born in a Western country with parents of Western ori-
gin (further referred to as Western-born), (2) born in a
Western country with one or both parents of non-Western
origin (second generation immigrant), and (3) born in a
non-Western country (first generation immigrant). West-
ern countries were defined as USA, Australia, Japan, Can-
ada, New Zealand, and European countries other than
Turkey, the Balkan States and countries of the former
Soviet Union. The size of the TST indurations was grouped
into three: 6–9 mm, 10–14 mm and 15 mm or more. The
presence of a scar was considered as evidence of BCG vac-
cination (scar/no scar) and self-reported known exposure
to an infectious tuberculosis case was reported as exposure
(yes/no). The accumulated duration of travels to non-
Western countries was grouped in three: none, or </> 3
months.
Unconditional multivariate analysis (logistic regression)
was performed with QFT as outcome variable. The inde-
pendent variables; origin, gender, BCG-vaccination, expo-
sure to tuberculosis and travel history were all included in
a preliminary multivariable regression analysis. Spearman
correlation coefficient was used to check for correlation
among pairs of independent variables. We subtracted one
variable at the time using the likelihood ratio test as elim-
ination criterion (p < 0.05). The same approach was used
to test the significance of the two-way interaction terms
between the independent variables in the final model.
This could not be run due to the low number of QFT pos-
itives. The odds ratios in the final model were used to
measure the strength of association. A separate univariate
regression analysis was performed to measure the strength
of association between QFT positivity and travel history
for Western-born and second generation immigrant chil-
dren.
Results
Study population and characteristics
The 33456 children in the catchment areas of the seven
participating hospitals constituted 53% of the children in
Norway born in 1991. They had the same gender distribu-
tion as all children born in 1991, while children with
immigrant parents were significantly overrepresented
(Table 1). Among the Western-born children 86% were
born in Norway, the remaining in other low-prevalence
countries mainly in Scandinavia and in USA. A total of
531 TST positive children were referred and 519 (98%)
consented to participate. Among 58 children with a posi-
tive first QFT-analysis, 16 (28%) had a negative result on
the confirmatory analysis of the same plasma sample and
the result was considered non-conclusive. Eight of them
submitted a new blood sample for QFT testing, two were
then positive and six negative. They are included in the
study group based on the result of the second test. The
remaining eight did not consent to repeat testing and were
excluded from the study. Thus, altogether 511 children
had a conclusive QFT result and formed the study group.
Among these 511 children, the median TST indurations
for unvaccinated children were 10 mm (range 6–30 mm)
and for previously BCG-vaccinated children 11 mm
(range 6–45 mm). First- and second generation immi-
grant children significantly more often presented with a
positive TST compared to Western-born children (Table
Table 1: Characteristics of source population and study group: number and prevalence of positive TST
Variable Population in nation 
born in 1991
Population in project 
area born in 1991
No. TST positives in 
project area
Prevalence of TST 
positives in project area
No. No. (%) No. % (95% CI)
Total 63662 33456 (53) 531 1.6 (1.5 – 1.7)
Gender
Male 32617 17127 (53) 286 1.7 (1.5 – 1.9)
Female 31045 16329 (53) 245 1.5 (1.3 – 1.7)
Origin of child
Western-born 57775 29712 (51) 288 0.9 (0.9 – 1.1)
Second generation
immigrant
2867 2052 (72) 111 5.4 (4.5 – 6.5)
First generation immigrant 3020 1692 (56) 132 7.8 (6.6 – 9.2)
Characteristics of children born in 1991 in nation and project area and 531 children referred because of positive tuberculin skin test result in the 
school based screening programme in Norway in the school year of 2005–6.Page 3 of 9
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disease during clinical evaluation or reported any previ-
ous history of tuberculosis.
Prevalence of positive QFT result
Only, 44 (9%) of the 511 TST positive children had a pos-
itive QFT result. Positive QFT tests were seen with all sizes
of TST indurations (Figure 1), although the proportion
increased with the size of the TST indurations in both gen-
ders and regardless of BCG vaccination and origin (Table
2). First generation immigrants significantly more often
had a positive QFT test (18% of the TST positives), in con-
trast to 6% among both Western-born and second gener-
ation immigrants. Among the 16 Western-born children
with positive QFT results, 15 were born in Norway. Seven
of these children came from one coastal city in Southern
Norway, which contributed to only 14% of the children in
the study. Three of them came from the same school
where additional nine children were identified with a pos-
itive TST, while the QFT turned out negative. They were all
assessed for history of symptoms or clinical findings con-
current with M. marinum, M. kansasii or M. szulgai infec-
tion, but none reported such. Discrepant results were
common even for TST reactions =>15 mm, of which only
22% had a positive QFT. Among the 83 participants with
TST =>15 mm and negative QFT, 31 were previously
unvaccinated.
Among the 16 children with a non-conclusive first QFT-
test, nine were Western-born, three were second and four
were first generation immigrants and none reported expo-
sure to tuberculosis. Their median TST indurations were
10 mm (range 6–20 mm). The IFN-γ levels in the first pos-
itive result varied between 0.35–0.5 IU IFN-γ/ml for
seven, between 0.5–1.0 IU IFN-γ/ml for five and higher
than 1 IU IFN-γ/ml for four of the children. For the two
children with a positive result in a new test, the level of
IFN-γ increased compared to the first test. Among the six
children who had a negative result in a new test the level
of IFN-γ in the first positive result differed widely.
Predictors of a positive QFT result
Altogether 46% of the TST positive children had a BCG-
scar, 84% among first generation immigrants, 89%
among second generation immigrants and 13% among
Western-born children (Table 2). Exposure to an infec-
tious case of tuberculosis was reported by 27 children.
Five out of seven children reporting exposure to a house-
hold contact had a positive QFT, while only two out of 20
if the source case was outside the household. Six out of
seven with exposure and a positive QFT were immigrants.
Immigrant children reported staying in non-Western
country prior to arrival to Norway with a median of 9
years (range 1 month-15 years). Second generation immi-
grant children (76%) reported travels to non-Western
countries more often than Western-born children (34%),
but the median accumulated duration of their travels was
comparable (6 weeks). Only origin and exposure to tuber-
culosis were associated with QFT positivity (Table 3).
Both BCG-vaccination and travel history were correlated
to origin (Spearman's rho 0.735 and 0.663 respectively)
and did not fit into the same model. Travel was not signif-
icantly associated with a positive QFT for Western-born or
second generation immigrant children in univariate
regression analysis (data not shown).
Three months preventive treatment with rifampicin and
isoniazid was prescribed for 61% of children with a posi-
tive QFT. Among first and second generation immigrant
and Western-born children with a positive QFT, the per-
centages were 83%, 80% and 19% respectively. The QFT-
Table 2: QuantiFERON®TB Gold positive results distributed by TST-induration, gender, BCG-status and origin
Total study group TST 6–9 mm TST 10–14 mm TST =>15 mm
Variable TST QFT+ TST QFT+ TST QFT+ TST QFT+
No. No. (%) 95% CI No. No. (%) No. No. (%) No. No. (%)
Study group 511 44 (9) 6.4 – 11.2 207 8 (4) 198 13 (7) 106 23 (22)
Gender
Male 275 21 (8) 4.9 – 11.2 110 6 (6) 110 7 (6) 55 8 (15)
Female 236 23 (10) 6.4 – 14.0 97 2 (2) 88 6 (7) 51 15 (29)
Origin of child
Western-born 280 16 (6) 3.4 – 8.9 131 6 (5) 110 7 (6) 39 3 (8)
Second generation immigrant 108 6 (6) 2.3 – 11.1 41 1 (2) 44 1 (2) 23 4 (17)
First generation immigrant 123 22 (18) 11.9 – 25.4 35 1 (3) 44 5 (11) 44 16 (36)
BCG-scar
Scar 236 23 (10) 6.4 – 14.0 80 2 (3) 89 5 (6) 67 16 (24)
No scar 262 18 (7) 4.2 – 10.4 125 6 (5) 101 7 (7) 36 5 (14)
Doubtful or no report 13 3 (23) 6.2 – 50.9 2 0 8 1 3 2
Number of QuantiFERON®TB Gold positive results among 511 tuberculin skin test positive children detected in the Norwegian school based 
screening programme in the school year of 2005–6.Page 4 of 9
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follow-up program. None of the QFT-negative children
were offered preventive treatment and further follow up
was terminated for the majority.
Discussion
In this study, we have shown that only 9% of TST positive
school children, including first and second generation
immigrants tested positive with the QuantiFERON®TB
Gold test. QFT positivity was associated with size of TST
Number of QuantiFERON®TB Gold positive results distributed by mm tuberculin skin test indurationFigur  1
Number of QuantiFERON®TB Gold positive results distributed by mm tuberculin skin test induration. Distribu-
tion of QuantiFERON®TB Gold results among 511 tuberculin skin test positive children detected in the Norwegian school 
based screening programme in the school year of 2005–6. Tuberculin skin test indurations measured as 25 mm or more were 
grouped together as 25 mm+.
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Table 3: Associations between background variables and positive QuantiFERON®TB Gold test
Variable Total QFT+ a OR p-value for variable
Origin of child 0.001
Western-born 280 16 ref
Second generation immigrant 108 6 0.9 (0.3 – 2.4)
First generation immigrant 123 22 3.3 (1.6 – 6.2)
Exposure 0.034
No 478 37 ref
Yes 27 7 2.9 (1.1 – 7.6)
Results from multivariate regression analysis with positive QuantiFERON®TB Gold test as outcome variable among 511 tuberculin skin test positive 
children detected in the Norwegian school based screening programme in 2005–6. Final model; 505 observations, p-value < 0.001 and Log 
likelihood =-139.20399Page 5 of 9
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exposure to tuberculosis.
Low prevalence of positive QFT-results
First and second generation immigrants were more likely
to have a positive TST reaction. Most of them are already
BCG-vaccinated, a factor known to affect the specificity of
TST. The assumption that factors other than tuberculosis
infection are widely contributing to positive TST reactions
among schoolchildren in Norway is supported by this
study, as only 9% of TST positive children also had a pos-
itive QFT. Thus, QFT seems to be more specific than TST.
Sensitivity or differences in the nature of the immune
response measured by the two tests should however also
be considered. Other studies from low-prevalence coun-
tries have reported moderate agreement between the tests,
but these studies have included mainly recent contacts or
patients with suspected tuberculous disease [6-10,12,14].
TST reactions caused by previous BCG-vaccination or
infections with NTM are expected to be moderate and in
the range of 6–14 mm [15-17], consistent with our study
where 79% of the positive TST reactions occurred within
this range. The effect of infant BCG-vaccination on TST is
perceived to be minimal, especially more than 10 years
after vaccination [18]. Contrary to our results, other stud-
ies have reported a significantly better agreement between
the tests for unvaccinated than vaccinated groups [8,19].
Different risk profile for tuberculosis exposure between
the vaccinated and unvaccinated participants in our study
may explain the lack of difference among the groups.
Infections from NTM could explain the high number of
TST positive children, as these infections are quite fre-
quent in Norway (250 notifications from laboratories
every year, unpublished data from the Tuberculosis Regis-
ter) compared to the 300 notified cases of tuberculosis.
They are endemic also in countries with high levels of
tuberculosis [20].
Among the children with TST =>15 mm, only 22% had a
positive QFT. This discordance is not easily explained by
poor specificity of TST since reactions exceeding 15 mm
have been interpreted as true tuberculosis infection [15-
17]. The sensitivity of QFT for detection of latent infection
has been extrapolated from data obtained from patients
with active disease and found to be variable (75 – 97%)
depending on the study population and design
[12,21,22]. Discrepant results between TST =>15 mm and
QFT have also been documented also in other studies
[20,23,24]. The two tests measure different immune
responses. Tuberculin induces a delayed-type hypersensi-
tivity reaction reflecting a memory response, while the
blood tests are believed to detect cellular IFN-γ release
reflecting an effector response to an ongoing infection.
Thus, IFN-γ release assays may detect recent and persistent
infection whereas TST react to previous infections
[7,12,25]. However, this may be of less relevance in our
study as the population studied is very young. The find-
ings illustrate the need for follow-up studies to better clar-
ify which criteria to be considered to diagnose latent
tuberculosis and possibly also guide the decision to offer
preventive treatment. The tests' potential ability to iden-
tify those at risk for progression to disease is of great inter-
est. Until July 2008 none of the participants have been
notified with tuberculosis disease in Norway.
None of the seven Western-born QFT positive cases from
the same coastal area reported exposure to tuberculosis
and careful source case investigations have revealed no
links or index case. The incidence rate of tuberculosis in
this region was lower than the national average, 4.3 per
100 000 population in 2006 [1], no recent outbreaks have
been reported from the area and no case of active tubercu-
losis has been reported from this school for decades.
There is no explanation why this city and school is over-
represented. Despite the high specificity of the QFT, we
cannot rule out false positive results caused by one of the
species that share the antigens used in the QFT assay with
the M. tuberculosis-complex [12,26]. The seven QFT-posi-
tive children were all healthy with normal chest X-rays,
they had no wounds or other symptoms of M. marinum,
M. szulgai, or M. kansasii infections or reported such his-
tory. This is a coastal area where children are often in con-
tact with sea water. One of the seven was a sports
swimmer, one had an aquarium, two were frequently fish-
ing, but none had clinical findings or reported history of
symptoms compatible with M. marinum infection, which
is normally fairly easy to diagnose.
In this study, QFT testing followed a tuberculin skin test.
Leyten found that the specificity of QFT was not affected
by prior TST administration [27]. Even though the ques-
tion is not completely resolved there is no evidence that
TST affects the QFT result. Having a QFT following a TST
is also in agreement with the European Consensus Report
[28].
Predictors of positive QFT
Origin of the child and known exposure to tuberculosis
were predictors of a positive QFT. We assume that most
first generation immigrant children with latent infection
were infected in their home country prior to arrival in
Norway. This is supported by results from Restricted Frag-
ment Length Polymorphism (RFLP) fingerprinting rou-
tinely performed on all M. tuberculosis isolates in Norway
since 1994, indicating that most tuberculosis cases are due
to importation of new strains rather than transmission
within Norway [3,4]. Second generation immigrant chil-
dren have been regarded as a risk group for tuberculosis
since the disease is mainly affecting the immigrant popu-Page 6 of 9
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ods to their parents country of origin and live close to the
indigenous population. Over the last five years, 4–5 cases
of tuberculosis disease have been reported annually
among second generation immigrant children in Norway,
compared to approximately one case among Western-
born children. In this study history of travel was not asso-
ciated with QFT positivity for any of the groups, even
though a substantial number reported accumulated dura-
tion of travel exceeding three months.
The study was based on a well-run, public, school-based
programme and enrolment was almost complete. The
validity of the TST-results can be debated since a lot of
public health nurses were involved in the screening, due
to the routine setting in which the study was conducted.
This is a limitation of the study. Even though none
reported non-standardised administration or reading of
TST, this can not be ruled out. A moderate digit preference
for different TST cut-offs was detected. We also believe
that some schools may not have tested previously BCG-
vaccinated children or not referred children with margin-
ally positive TST-results. Thus, we may have missed some
TST-positive children.
Even though only few participants reported exposure to
an infectious case of tuberculosis, this was, as reported in
other studies, significantly related to a positive QFT
[6,8,9,19,29]. Cultural concepts of "being exposed" may
differ since none of the Western-born children and only
one of the second generation children reporting exposure
were QFT positive. With only 44 QFT positives in the
study group of 511 children, however, we had limited
power to detect associations between background varia-
bles and QFT positivity. Importantly, we observed a sig-
nificant association between the increase in TST
indurations and the proportion of QFT positive. This is
consistent with the expected association between the
increase in TST indurations and the proportion of tuber-
culin reactions caused by M. tuberculosis [30]. As positive
mitogen control was not available as a part of the assay
used in this study, we may theoretically have missed some
QFT positives. However, this is not so relevant in this pop-
ulation where all participants were TST positive and
immunosuppression is considered to be very rare.
Reproducibility
It is a concern that it was only possible to reproduce a pos-
itive result on the same plasma sample in 72% of the
cases. A potential discordance occurring at or near to the
cut-off value is probably as expected and is also described
in other studies [31,32]. Still, we had some initially mod-
erate and a few strongly positive results which we were not
able to reproduce, not in repeat analysis of the same sam-
ple or for some, in a new test. We do not know to what
extent repeated testing of initially negative results also
would show inconsistency and how that could have
affected the outcome of our study. Among the eight par-
ticipants who consented to a new test the time between
collections of the two samples differed, but none reported
any risk of exposure during the period.
The risk of tuberculosis infection and recent exposure is
generally low in this study group. In a previous study we
have performed among asylum seekers arriving from high
incidence countries, we observed a lower proportion
(3,7%) of non-conclusive QFT results [33]. This may indi-
cate that the reproducibility of QFT testing can differ
between study groups representing differences in inci-
dence and/or levels of positive QFT results. In general dis-
cordant results are difficult to interpret and need to be
evaluated in larger studies designed for this purpose.
It will not be a standard procedure in a normal screening
setting to confirm all positive results by re-analysis of the
same plasma sample. This was however done in this study
since we assumed that a positive QFT result potentially
would increase the likelihood of preventive treatment.
QFT is a new test with few data from screening among
children and we felt that retesting positive samples would
provide more valid results. We assessed the potential
impact of this modification in the study by including the
16 participants with an initial non-conclusive first QFT
result as QFT-positives in an additional analysis (data not
shown). While the numbers and proportions of QFT pos-
itives increased, most among Western-born children,
there were no significant changes of proportions of posi-
tive tests by gender, origin or BCG-scar. In the multivariate
analysis exposure was no longer a predictor for a positive
QFT while origin remained significant. Thus, including
the 16 cases as positives would not materially change the
interpretation of the results or the main conclusions of the
study.
Implications for the screening programme
The study suggests that the prevalence of latent infection
among 9th grade school children in Norway is very low
and that TST screening results in many false positive reac-
tions. Preventive treatment was almost exclusively given
to children with immigrant background. Few Western-
born children with positive TST and QFT were offered pre-
ventive treatment. This probably reflects; (1) no identified
source of exposure, (2) an assessment of low risk of sub-
sequent development to active disease and (3) parents not
accepting preventive treatment when offered. These
results are relevant for the discussion on the usefulness of
the screening since identification of children with latent
infection for preventive treatment has been one of the
aims of the programme. Thus, the current screening pro-
gramme may not be justified and cost studies are needed.Page 7 of 9
(page number not for citation purposes)
BMC Infectious Diseases 2008, 8:140 http://www.biomedcentral.com/1471-2334/8/140We believe that the few children where infection with M.
tuberculosis is most likely, may be identified by improved
immigrant entry-screening and testing of contacts of cases
with infectious tuberculosis. The usefulness of TST as pre-
screening before routine BCG vaccination needs to be
carefully evaluated in conjunction with the current evalu-
ation of the BCG vaccination programme as a whole.
Conclusion
Our results indicate that factors other than tuberculosis,
such as NTM infection or previous BCG-vaccination, are
widely contributing to positive TST results among chil-
dren in Norway. The poor agreement between TST and
QFT tests is therefore mainly explained by the increased
specificity of the QFT. Latent infection seems to be almost
absent among Western-born TST positive children,
including second generation immigrants, while first gen-
eration immigrant children are at increased risk. First gen-
eration immigrant children are already targeted by entry
screening and improved programme performance of this
screening is a better control measure in a low prevalence
country. The study supports the need to evaluate the cur-
rent national screening and BCG-vaccination programme
in Norway.
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